Adherex Meets with Health Canada to Discuss Phase I Clinical Trials for Exherin.Business Editors & Health/Medical Writers Adherex Technologies Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :AHX AHX American History X (movie) AHX Abyss' Highest eXperience ), a biotechnology company developing novel therapeutics based on cell adhesion Cellular adhesion is the binding of a cell to another cell or to a surface or matrix. Cellular adhesion is regulated by specific adhesion molecules that interact with molecules on the opposing cell or surface. technology, met with Health Canada today to discuss plans for Phase I human clinical trials for its cancer therapy drug, Exherin(TM). Exherin(TM) is a potentially ground-breaking therapy for arresting the growth of cancer tumors by cutting off tumor blood supply. At the Health Canada meeting, Exherin(TM) efficacy studies in animals, clinical trial protocols, manufacturing procedures and safety studies were reviewed. "Our team is very pleased with Health Canada's response to our proposals," said Dr. Robin Norris, President and COO of Adherex. "We feel confident that our ongoing R&D program will supply the necessary requirements for our regulatory filing and that we remain on track to commence clinical trials by the end of this year." Assuming regulatory approval is granted, Phase I clinical trials are expected to begin before the end of the year at the Ottawa Regional Cancer Centre The Regional Cancer Centre(RCC), was established in 1981 by the Government of Kerala and Government of India at Thiruvananthapuram(Trivandrum), the capital of Kerala. The RCC deals with the treatment of Cancer in the states of Kerala, Tamil Nadu and Karnataka. with Dr. David Stewart as the lead investigator. Dr. Stewart is a Medical Oncologist medical oncologist Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. at the Ottawa Regional Cancer Centre and Professor of Medicine at the University of Ottawa About Adherex Technologies Adherex Technologies is an Ottawa-based biotechnology company that develops therapeutic drugs based upon its proprietary cell adhesion platform technology. The lead compound, Exherin, works to destroy the blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. that feed a cancerous tumor, essentially destroying the tumor's food supply. Adherex's unique cell adhesion platform has the potential for diverse applications, including drug delivery through the skin. For more information, please visit Adherex's Web site at www.adherex.com. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion